Search

Your search keyword '"Church, David N"' showing total 278 results

Search Constraints

Start Over You searched for: Author "Church, David N" Remove constraint Author: "Church, David N"
278 results on '"Church, David N"'

Search Results

1. The genomic landscape of 2,023 colorectal cancers

2. Non-Canonical Activin A Signaling Stimulates Context-Dependent and Cellular-Specific Outcomes in CRC to Promote Tumor Cell Migration and Immune Tolerance.

3. Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer

4. Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts

5. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis

6. Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study

7. IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma

8. Patterns of cytotoxic T-cell densities in immunogenic endometrial cancers reveal a potential mechanism for differences in immunotherapy efficacy

10. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients

11. Promises and challenges of adoptive T-cell therapies for solid tumours

12. The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer

14. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study

15. The English National Lynch Syndrome transformation project: an NHS Genomic Medicine Service Alliance (GMSA) programme

16. Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis

17. Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study

20. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series

23. Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets

26. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study

27. Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer

28. Data from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

29. Supplementary Table 7 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

30. Supplementary Tables 1-6, 8 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

31. Supplementary Figures from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

32. Supplementary Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer

33. Supplementary figure 6 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

34. Supplementary Table S2 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

35. Table S3 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

36. Supplementary figure 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

37. Figure S1 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

38. Supplementary figure 4 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

39. Supplementary table 2 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

40. Supplementary Figure S2 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

41. Supplementary figure 5 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

42. Supplementary Methods from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

43. Supplementary Methods from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

44. Supplementary figure 2 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

45. Supplementary figure 3 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

46. Supplementary table 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Catalog

Books, media, physical & digital resources